Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Inclusion Criteria: * Previously untreated, histologically confirmed indolent non-Hodgkin's lymphoma as follows: * Follicular lymphoma (World Health Organization \[WHO\] classification grade 1, 2, or 3a) * Marginal zone lymphoma including: * Nodal and splenic marginal zone lymphoma (MZL) who have an indication for systemic therapy * Extranodal MZL: * Nongastric/noncutaneous MZL requiring systemic therapy * Cutaneous MZL will be eligible only if they have pathologically confirmed extra-cutaneous disease * Gastric MZL only if stage IIIE/IV defined as lymph node involvement on both sides of the diaphragm or with disseminated extranodal disease such as bone marrow or additional extra nodal sites * Pathological diagnosis should be obtained by incisional or excisional tissue biopsy; core biopsy is permissible if obtaining an incisional or excisional is not possible and if the grade can be assessed on the core biopsy; a core biopsy can also be used if deemed in the best interest of the patient in the opinion of the investigator * Patients must have stage II-IV disease * All patients should have measurable disease; measurable disease is defined as a lymph node or tumor mass that is \>= 1.5 cm in at least one dimension by computed tomography (CT) or the CT portion of the PET/CT * Documentation of CD20+ status * Patients must have an indication for therapy per standard modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria including: * …